Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
BACKGROUND: Trastuzumab resistance hampers its well-known efficacy to control HER2-positive breast cancer. The involvement of PI3K/Akt pathway in this mechanism is still not definitively confirmed. METHODS: We selected 155 patients treated with trastuzumab after development of metastasis or as adjuv...
| Autores: | , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2012 |
| País: | España |
| Institución: | Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau) |
| Repositorio: | r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau |
| OAI Identifier: | oai:iibsantpau.fundanetsuite.com:p11399 |
| Acceso en línea: | https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11399 http://ddd.uab.cat/record/184827 |
| Access Level: | acceso abierto |
| Palabra clave: | breast cancer HER2 EGFR IGF1R PTEN/PI3K/Akt pathway trastuzumab resistance |
| Sumario: | BACKGROUND: Trastuzumab resistance hampers its well-known efficacy to control HER2-positive breast cancer. The involvement of PI3K/Akt pathway in this mechanism is still not definitively confirmed. METHODS: We selected 155 patients treated with trastuzumab after development of metastasis or as adjuvant/neoadjuvant therapy. We performed immunohistochemistry for HER2, ER/PR, epidermal growth factor 1-receptor (EGFR), alpha-insulin-like growth factor 1-receptor (IGF1R), phosphatase and tensin homologue (PTEN), p110 alpha, pAkt, pBad, pmTOR, pMAPK, MUC1, Ki67, p53 and p27; mutational analysis of PIK3CA and PTEN, and PTEN promoter hypermethylation. RESULTS: We found 46% ER/PR-positive tumours, overexpression of EGFR (15%), alpha-IGF1R (25%), p110 alpha (19%), pAkt (28%), pBad (22%), pmTOR (23%), pMAPK (24%), MUC1 (80%), PTEN loss (20%), and PTEN promoter hypermethylation (20%). PIK3CA and PTEN mutations were detected in 17% and 26% tumours, respectively. Patients receiving adjuvant trastuzumab with alpha-IGF1R or pBad overexpressing tumours presented shorter progression-free survival (PFS) (all P <= 0.043). Also, p110a and mTOR overexpression, liver and brain relapses implied poor overall survival (OS) (all P <= 0.041). In patients with metastatic disease, decreased PFS correlated with p110 alpha expression (P = 0.024), whereas for OS were the presence of vascular invasion and EGFR expression (P <= 0.019; Cox analysis). CONCLUSION: Our results support that trastuzumab resistance mechanisms are related with deregulation of PTEN/PI3K/Akt/mTOR pathway, and/or EGFR and IGF1R overexpression in a subset of HER2-positive breast carcinomas. British Journal of Cancer (2012) 106, 1367-1373. doi: 10.1038/bjc.2012.85 www.bjcancer.com Published online 27 March 2012 (C) 2012 Cancer Research UK |
|---|